An Observational, Non-Interventional Trial to Assess Patient Satisfaction and Safety of Subsys (TM) Spray Compared to Actiq (RM) for the Management of Breakthrough Pain in Chronic Pain Patients.
Phase of Trial: Phase IV
Latest Information Update: 10 Sep 2014
Price : $35 *
At a glance
- Drugs Fentanyl (Primary)
- Indications Cancer pain
- Focus Therapeutic Use
- 10 Sep 2014 Status changed from active, no longer recruiting to discontinued.
- 16 Aug 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov registry record.
- 27 Jul 2013 New trial record